MGX Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

7.40M

-23.07%

-0.585

-7.14%

5.00M

+21.15%

-0.620

-8.82%

-0.620

+14.81%

Estimates Revision

The market is revising Downward the revenue expectations for Metagenomi, Inc. (MGX) for FY2025, with the revenue forecasts being adjusted by -5.23% over the past three months. During the same period, the stock price has changed by -43.45%.

Revenue Estimates for FY2025

Revise Downward

-5.23%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.52%

In Past 3 Month

Stock Price

Go Down

-43.45%

In Past 3 Month

4 Analyst Rating

Wall Street analysts forecast MGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGX is 8.67 USD with a low forecast of 7.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

7.00

Averages

8.67

High

12.00

Current: 0.000

Low

7.00

Averages

8.67

High

12.00

Chardan

Geulah Livshits

Buy

downgrade

$11 -> $7

2025-11-12

Reason

Chardan

Geulah Livshits

Price Target

$11 -> $7

2025-11-12

downgrade

Buy

Reason

Chardan analyst Geulah Livshits lowered the firm's price target on Metagenomi to $7 from $11 and keeps a Buy rating on the shares after the company reported Q3 results, announced the appointment of Dr. Jian Irish to CEO, and shared updated preclinical data on lead in vivo insertion program MGX-001 in hemophilia A. The firm updated its model for Q3 financials and removed the majority of platform value from the model in light of prioritization.

Chardan

downgrade

$12 -> $11

2025-08-15

Reason

Chardan

Price Target

$12 -> $11

2025-08-15

downgrade

Reason

Chardan lowered the firm's price target on Metagenomi to $11 from $12. The firm updated its model for Q2 financials and takes a slightly more conservative stance on programs/platform beyond hem A and the Ionis collaboration in light of the company's increasing focus on pipeline execution and advancing gene editing platform competition. The firm noted its Q2 adjustments shift its price target lower.

Wells Fargo

Yanan Zhu

Overweight

downgrade

$20 -> $16

2025-05-14

Reason

Wells Fargo

Yanan Zhu

Price Target

$20 -> $16

2025-05-14

downgrade

Overweight

Reason

Wells Fargo analyst Yanan Zhu lowered the firm's price target on Metagenomi to $16 from $20 on updated model assumption, while keeping an Overweight rating on the shares. The firm notes updated NHP data from the Hem A program demonstrate stable FVIII levels out to 19 months, boding well for a differentiated product profile and also providing preclinical validation for the secreted protein platform.

HC Wainwright & Co.

Mitchell Kapoor

Strong Buy

Maintains

$14 → $7

2025-04-03

Reason

HC Wainwright & Co.

Mitchell Kapoor

Price Target

$14 → $7

2025-04-03

Maintains

Strong Buy

Reason

Wells Fargo

Yanan Zhu

Buy

Maintains

$25 → $20

2025-03-18

Reason

Wells Fargo

Yanan Zhu

Price Target

$25 → $20

2025-03-18

Maintains

Buy

Reason

Wells Fargo analyst Yanan Zhu lowered the firm's price target on Metagenomi (MGX) to $20 from $25 and keeps an Overweight rating on the shares. With key initiatives progressing on track, the firm looks forward to the final NHP FVIII durability analysis in the first half of 2025 as well as updates on Ionis (IONS) collaboration programs and preclinical PoC for a secreted protein deficiency target this year.

Valuation Metrics

The current forward P/E ratio for Metagenomi Inc (MGX.O) is -0.67, compared to its 5-year average forward P/E of -1.29. For a more detailed relative valuation and DCF analysis to assess Metagenomi Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-1.29

Current PE

-0.67

Overvalued PE

-0.37

Undervalued PE

-2.21

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.28

Current EV/EBITDA

0.80

Overvalued EV/EBITDA

2.28

Undervalued EV/EBITDA

-1.72

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.89

Current PS

2.80

Overvalued PS

6.20

Undervalued PS

1.58

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 323.12% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

MGX News & Events

Events Timeline

No data

News

2.0

2025-12-09NASDAQ.COM

After-Hours Stock Surge: Exicure Leads with 72% Increase, Followed by Wave Life and Assembly Biosciences

3.5

2025-12-02WSJ

Amazon's Custom Chips Present a New Challenge for Nvidia

2.0

2025-12-01NASDAQ.COM

Biotech Stocks Surge in After-Hours Trading with Gains from BioAtla, Entero, and Sonnet

People Also Watch

Frequently Asked Questions

What is Metagenomi Inc (MGX) stock price today?

The current price of MGX is 1.77 USD — it has decreased -1.67 % in the last trading day.

What is Metagenomi Inc (MGX)'s business?

Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.

What is the price predicton of MGX Stock?

What is Metagenomi Inc (MGX)'s revenue for the last quarter?

Metagenomi Inc revenue for the last quarter amounts to 8.66M USD, decreased -24.80 % YoY.

What is Metagenomi Inc (MGX)'s earnings per share (EPS) for the last quarter?

Metagenomi Inc. EPS for the last quarter amounts to -0.55 USD, increased 7.84 % YoY.

What changes have occurred in the market's expectations for Metagenomi Inc (MGX)'s fundamentals?

How many employees does Metagenomi Inc (MGX). have?

Metagenomi Inc (MGX) has 202 emplpoyees as of January 09 2026.

What is Metagenomi Inc (MGX) market cap?

Today MGX has the market capitalization of 66.46M USD.